Given the higher potency of Ruxolitnib (Jak1/2 inhibitor) over Tofacitinib (Jak2/3 inhibitor) in vitro and ex vivo, JAK1 and JAK2 protein expression was investigated in a large retrospective cohort of CRC patient tissue (cohort 1) (n = 1030) (Additional Fig. S4A). Here, JAK1 is linked to colorectal carcinoma.